Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

HM, Kantarjian; NP, Shah; JE, Cortes; M, Baccarani; MB, Agarwal; MS, Undurraga; J, Wang; JJ, Ipiña; DW, Kim; M, Ogura; C, Pavlovsky; C, Junghanss; JH, Milone; FE, Nicolini; T, Robak; Droogenbroeck J, Van; E, Vellenga; MB, Bradley-Garelik; C, Zhu; A, Hochhaus

doi:10.1182/blood-2011-08-376087

Public

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Shared by NobleBlocks on Dec 9, 2011 • 12:00 AM UTC

Authors:

Kantarjian HM

Shah NP

Cortes JE

Abstract

Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 DASISION trial, patients with newly diagnosed chronic-phase (CP) CML were randomized to receive dasatinib 100 mg (n = 259...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!